Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize

Anjali T Owens1, Milind Desai2, Matthew T Wheeler3

  • 1University of Pennsylvania Perelman School of Medicine Philadelphia PA USA.

Insights

Mavacamten offers a new treatment for obstructive hypertrophic cardiomyopathy. An echocardiography-guided dosing strategy optimizes benefits and safety by monitoring left ventricular outflow tract gradient and ejection fraction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Diagnostics

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) is a significant cardiovascular condition.
  • Mavacamten is a novel cardiac myosin inhibitor approved for symptomatic NYHA class II-III oHCM.
  • Individualized dosing is crucial for optimizing therapeutic outcomes and safety.

Purpose of the Study:

  • To develop and validate an echocardiography-based, clinically guided dose-titration strategy for mavacamten.
  • To optimize patient benefit in symptomatic obstructive hypertrophic cardiomyopathy.
  • To minimize the risk of left ventricular ejection fraction reduction.

Main Methods:

  • Utilized evidence-based rationale and clinical parameters for dosing.
  • Employed echocardiography to monitor left ventricular (LV) outflow tract gradient and LV ejection fraction.
  • Incorporated clinical trial data, modeling, and simulation analyses.

Main Results:

  • The echocardiography-based strategy successfully identified individualized mavacamten doses for improved outcomes.
  • Demonstrated improvements in LV outflow tract obstruction, functional capacity, and symptoms.
  • Showcased a favorable safety profile, irrespective of CYP2C19 metabolizer status.

Conclusions:

  • An echocardiography-guided dose-titration strategy effectively optimizes mavacamten therapy for oHCM.
  • This approach balances therapeutic efficacy with the mitigation of adverse effects like reduced LV ejection fraction.
  • The strategy accounts for patient-specific factors including CYP2C19 metabolism and potential drug interactions.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322